{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreib3aea7gbrr7towdrcie44uyrxoa3cbtzc73go3b4cqzmoc4xbnna",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3menzn6emxct2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidwk7pg4dme6e63ybkaeanufh5sp3zng2hyurq6pjnqjwg55yousu"
    },
    "mimeType": "image/jpeg",
    "size": 93173
  },
  "path": "/2026/02/12/bridgebio-dwarfism-achondroplasia-infigratinib/?utm_campaign=rss",
  "publishedAt": "2026-02-12T12:30:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "biotechnology",
    "Pharmaceuticals",
    "rare diseases",
    "STAT+"
  ],
  "textContent": "BridgeBio Pharma’s experimental drug for the most common cause of dwarfism accelerated children’s growth in a pivotal clinical trial.",
  "title": "STAT+: BridgeBio drug for genetic cause of dwarfism succeeds in key study",
  "updatedAt": "2026-02-11T23:42:56.000Z"
}